- ROS1 - another potencional target of our patients2014 | Faculty of Medicine in Pilsen
- Successful Therapy of Czech Patients with ROS1 Translocation by Crizotinib2016 | Faculty of Medicine in Pilsen
- Entrectinib in the treatment of patients with ROS1‑positive advanced non‑small cell lung cancer2021 | Publication without faculty affiliation
- Optimal procedure in treatments of advanced ALK-positive and ROS1-positive non-small cell lung cancers2019 | Third Faculty of Medicine
- Pacient s diseminovaným NSCLC s fúzí ROS1 s téměř kompletní remisí na biologické léčbě - kazuistika2021 | Publication without faculty affiliation
- Entrectinib v léčbě ROS1 pozitivního pokročilého nemalobuněčného plicního karcinomu a v léčbě solidních nádorů s NTRK fúzí2021 | First Faculty of Medicine
- Modern treatment of non-small cell lung carcinoma2017 | Faculty of Medicine in Pilsen
- Testing for ROS1 in non-small cell lung cancer: a review with recommendations2016 | Faculty of Medicine in Hradec Králové
- Crizotinib - a novel multikinase inhibitor of signalling pathways for treatment in selected patients with non-small cell lung cancwer2013 | Faculty of Medicine in Pilsen
- Current status and prospects of targeted therapies non-small cell lung cancer2016 | Faculty of Medicine in Pilsen
- Nemalobuněčný karcinom plic s přestavbou genu ALK a ROS1, léčený lorlatinibem2019 | Second Faculty of Medicine
- Crizotinib - a multitargeted inhibitor as a molecularly targeted treatment in non small cell lung cancer2013 | Publication without faculty affiliation
- A targeted diagnostic procedure and a treatment of an advanced lung carcinoma -the case report of a successful cooperation of four clinic departments, and crizotinib in a treatment of ROS 1 positive NSCLC2018 | Faculty of Medicine in Pilsen, First Faculty of Medicine
- Molecular pathology of lung cancer in routine diagnostic practice: 2017 update2017 | First Faculty of Medicine
- The current standard of NSCLC pathological examination in the Czech Republic2022 | Faculty of Medicine in Hradec Králové
- Non-small cell lung cancer with ALK and R0S1 genes rearregement2018 | Faculty of Medicine in Pilsen
- Staining Performance of ALK and ROS1 Immunohistochemistry and Influence on Interpretation in Non-Small-Cell Lung Cancer2020 | Faculty of Medicine in Hradec Králové
- Nemalobuněčný karcinom plic ROS1 pozitivní, léčený crizotinibem - kazuistika2018 | Second Faculty of Medicine
- Lorlatinib2019 | Second Faculty of Medicine
- Lorlatinib in the treatment of non-small cell lung cancer2019 | Second Faculty of Medicine
- Spitz tumors with ROS1 fusions: a clinicopathological study of 6 cases, including FISH for chromosomal copy number alterations and mutation analysis using next-generation sequencing2020 | Faculty of Medicine in Pilsen, First Faculty of Medicine, Central Library of Charles University
- Pacient s generalizovaným nemalobuněčným karcinomem plic s fúzí ROS1 s výbornou klinickou i zobrazovací odpovědí na léčbě entrektinibem2021 | Publication without faculty affiliation
- Crizotinib in the treatment of generalized non-small-cell lung cancer - a case report2017 | Publication without faculty affiliation
- What brings modern therapy to advanced non small cell lung cancer2017 | Faculty of Medicine in Pilsen
- Komentář ke studii2023 | First Faculty of Medicine
- Lorlatinib in a pretreated patient with ALK-positive lung adenocarcinoma2021 | Third Faculty of Medicine
- Entrectinib2020 | First Faculty of Medicine
- Immunotherapy in the first line treatment of non-small cell lung cancer2020 | Faculty of Medicine in Pilsen
- Strategy of treatment in metastatic non-small cell lung cancer with driver mutations2016 | Faculty of Medicine in Pilsen
- Systemic therapy of lung adenocarcinoma2016 | Faculty of Medicine in Pilsen